BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Oct 31, 2005
 |  BioCentury  |  Finance

EPS watch

EPS watch

EPS watch
Seven companies missed their respective consensus estimates last week. In addition, a few companies lowered their forward looking guidance. Biosite (BSTE) was the hardest hit, losing 21% of its valuation after disclosing that growth of its Triage BNP test will be slower than expected. Mcap in $M; (A) Results for 1Q06, ending Sept. 30.
Company 3Q05 EPS est 3Q05 EPS actual Outcome Growth from 3Q04 10/28 cls Wk chg % chg Mcap chg 10/28 mcap
Amylin (AMLN) -$0.58 -$0.65 Missed by $0.07 NA $33.52 -$2.53 -7% -$268.85 $3,561.97
In its first full quarter on the market, diabetes drug Byetta posted sales of $18.1M. The figure was below the expectations of a handful of analysts, which likely prompted investors to punish the stock (see "Analyst Picks," A17, and "Byetta Through Dark Glasses, A8).
Applied Biosystems (ABI) (A) $0.21 $0.24 Beat by $0.03 33% $23.99 $1.09 5% $213.1 $4,691.1
Revenues for 1Q06 ended Sept. 30 were $416M, up 6% from $390M in the same period last year. For FY06, the tool and reagent company expects revenue growth in the low to mid- single digits.
AstraZeneca (LSE:AZN; AZN) $0.67 $0.76 Beat by $0.09 52% $44.43 -$1.41 -3% -$2,292.7 $72,243.2
3Q05 sales rose 9% to $5.8B from $5.3B in 3Q04. For the full year, AZN provided more clarity about its EPS guidance. The company expects to report FY05 EPS of $2.85-$2.95. Previously, it had only said that FY05 EPS would be above $2.75.
Biogen Idec (BIIB) $0.42 $0.36 Missed by $0.06 -3% $38.49 -$0.60 -2% -$201.9 $12,953.3
3Q05 revenues were up 10% to $596M from $543M in 3Q04. Multiple sclerosis (MS) drug Avonex posted 3Q05 sales of $375M, up 8% vs. $346M in the...

Read the full 1722 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >